As Masimo works to fend off a proxy fight from Politan Capital Management, nearly 300 of the medtech’s engineers and global managers—as well as its chief operating officer—have signed on to letters saying they might follow founder and CEO Joe Kiani out the door if he is ousted from his position.

GSK is paying 400 million euros ($430 million) upfront for full rights to CureVac’s vaccines against influenza and COVID-19. The mRNA specialist shared news of the deal alongside a restructuring that will put 30% of its employees out of work and extend its cash runway into 2028.

Moderna has become the latest biopharma to benefit from the U.S. Department of Health and Human Services’ concerns about avian flu, awarding the company $176 million to fund the clinical development of a potential vaccine.

Merck & Co. is partnering with newly emerged N-Power Medicine on cancer clinical trials, according to a July 1 announcement.

Fortrea has launched a new research and development arm aimed at creating artificial-intelligence-driven clinical trial technologies that make studies speedier, safer and more efficient.

Contract research organizations aiming to get into the decentralized trials game in the U.S. may find the biggest opportunity in the Great Plains and on Native American reservations—parts of the country with high disease prevalence but where patients likely have to travel long distances to participate in a clinical trial, a Milken Institute report (PDF) published June 24 suggests.

Eli Lilly is continuing to pursue its newfound passion for radiopharmaceuticals, this time handing Radionetics Oncology $140 million in upfront cash to partner on its pipeline of G protein coupled receptor (GPCR) targeted drugs.

Artiva Biotherapeutics has become the latest biotech to set out IPO ambitions for the summer, as the allogeneic natural killer (NK) cell therapy company pushes its lead program through automimmune clinical trials.

Johnson & Johnson has presented phase 3 data on nipocalimab in generalized myasthenia gravis (gMG), providing a look at how its $6.5 billion prospect matches up to the approved FcRn rivals from argenx and UCB.

Bristol Myers Squibb is walking away from its $650 million bet on an Eisai antibody-drug conjugate (ADC). The Japanese drugmaker said BMS decided to end the co-development agreement as part of an ongoing portfolio prioritization push.